PRMSS, Anuradha College of Pharmacy, Chikhli, Dist. Buldhana, Maharashtra, India.
International Journal of Science and Research Archive, 2025, 14(01), 1205-1207
Article DOI: 10.30574/ijsra.2025.14.1.0173
Received on 05 December 2024; revised on 17 January 2025; accepted on 20 January 2025
This study investigates the development of poly (lactic-co-glycolic acid) (PLGA) nanoparticles functionalized with folic acid for targeted cancer therapy. Dual drug loading of doxorubicin and curcumin enhanced therapeutic efficacy through synergistic action. Nanoparticles were characterized for size, zeta potential, drug release kinetics, and targeting efficiency. Results demonstrated high drug encapsulation efficiency (89% for doxorubicin and 82% for curcumin), sustained release under physiological conditions (48% over 48 hours at pH 7.4), and enhanced cytotoxicity (IC50 = 11.4 µg/mL) against folate receptor-expressing MCF-7 cells. This approach addresses key challenges in nanoparticle-based therapy, including biocompatibility, precise targeting, and minimizing systemic toxicity.
Nanoparticles; Targeted Drug Delivery; Folic Acid; PLGA; Biocompatibility; Cancer Therapy; Cytotoxicity
Preview Article PDF
Atharva Vishnu Patil, Rushikesh Sudhakar Sapkal, K R Biyani and F A Shaikh. Targeted cancer therapy using nanoparticles: Addressing biocompatibility, targeting efficiency and toxicity. International Journal of Science and Research Archive, 2025, 14(01), 1205-1207. Article DOI: https://doi.org/10.30574/ijsra.2025.14.1.0173.
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0